益佰制药收到贵州省药品监督管理局《暂停生产、销售通知书》

Group 1 - The company received a suspension notice for the production and sale of its pediatric cough syrup from the Guizhou Provincial Drug Administration due to non-compliance issues identified during an inspection by the National Medical Products Administration [1][2] - The notice indicates that the company failed to accurately fill out certain records and did not use reliable methods for electronic data recording, leading to a conclusion of non-compliance [2] - The suspension is based on specific regulations that allow for such actions in cases of identified safety risks [2] Group 2 - The pediatric cough syrup generated revenues of 3.42 million, 4.32 million, 8.38 million, and 1.51 million yuan in the years 2021, 2022, 2023, and 2024, respectively, accounting for 0.10%, 0.16%, 0.30%, and 0.07% of the company's total consolidated revenue during those years [3] - The impact of the suspension on the company's overall performance is expected to be minimal due to the relatively small revenue contribution from the pediatric cough syrup [3]